title: Analog of neuropeptide FF attenuates morphine abstinence syndrome.
abstract: The octapeptide FLFQPQRFamide (neuropeptide FF or F8Fa) may play a role in opiate dependence and subsequent abstinence syndrome. Previously, NPFF precipitated opiate abstinence syndrome, while IgG from NPFF antiserum attenuated subsequent naloxone-precipitated abstinence signs in dependent rats. The peptide desamino YFLFQPQRamide (daY8Ra) was synthesized as a possible NPFF antagonist. At a dose of 600 ng ICV, daY8Ra significantly attenuated (p less than 0.001) the number of abstinence-like signs subsequently induced by 10 micrograms NPFF ICV, suggesting that daY8Ra does have antagonist activity against NPFF. Pretreatment of morphine-dependent rats with the same dose of daY8Ra also significantly attenuated (p less than 0.001) the abstinence signs subsequently precipitated by 10 micrograms naloxone ICV. Pretreatment with 600 ng of NPFF itself, or of NPFF modified at the N-terminal only (daY9Fa), failed to attenuate subsequent naloxone-precipitated abstinence, suggesting that the C-terminal modification is critical for NPFF antagonist activity. It should be noted, however, that higher doses of daY8Ra (2 micrograms or more) can precipitate some abstinence signs in a manner similar to NPFF.
authors.affiliation: University of Houston, Clear Lake, TX 77058.
authors.forename: D H
authors.initials: DH
authors.lastname: Malin
authors.forename: J R
authors.initials: JR
authors.lastname: Lake
authors.forename: J E
authors.initials: JE
authors.lastname: Leyva
authors.forename: M V
authors.initials: MV
authors.lastname: Hammond
authors.forename: R B
authors.initials: RB
authors.lastname: Rogillio
authors.forename: K R
authors.initials: KR
authors.lastname: Arcangeli
authors.forename: K
authors.initials: K
authors.lastname: Ludgate
authors.forename: G M
authors.initials: GM
authors.lastname: Moore
authors.forename: K
authors.initials: K
authors.lastname: Payza
mesh_terms: D000595:Amino Acid Sequence; D000818:Animals; D002552:Cerebral Ventricles / Q000187:drug effects / Q000502:physiology* / Q000503:physiopathology; D007276:Injections, Intraventricular; D008297:Male; D008969:Molecular Sequence Data; D009020:Morphine / Q000494:pharmacology; D009021:Morphine Dependence / Q000503:physiopathology*; D009270:Naloxone / Q000494:pharmacology; D009842:Oligopeptides / Q000008:administration & dosage / Q000138:chemical synthesis / Q000494:pharmacology*; D051381:Rats; D011919:Rats, Inbred Strains; D013375:Substance Withdrawal Syndrome / Q000503:physiopathology* / Q000517:prevention & control
chemical_list: D009842:Oligopeptides; C073647:desamino-tyrosyl-phenylalanyl-leucyl-phenylalanyl-glutaminyl-prolyl-glutaminyl-argininamide; D009270:Naloxone; D009020:Morphine; C053651:phenylalanyl-leucyl-phenylalanyl-glutaminyl-prolyl-glutaminyl-arginyl-phenylalaninamide